Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Debt (2022 - 2025)

Taysha Gene Therapies' Non-Current Debt history spans 4 years, with the latest figure at $50.9 million for Q3 2025.

  • For Q3 2025, Non-Current Debt rose 18.34% year-over-year to $50.9 million; the TTM value through Sep 2025 reached $50.9 million, up 18.34%, while the annual FY2024 figure was $43.9 million, 8.48% up from the prior year.
  • Non-Current Debt for Q3 2025 was $50.9 million at Taysha Gene Therapies, up from $41.1 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $50.9 million in Q3 2025 and bottomed at $37.4 million in Q1 2022.
  • The 4-year median for Non-Current Debt is $38.5 million (2023), against an average of $40.4 million.
  • The largest annual shift saw Non-Current Debt decreased 1.35% in 2024 before it grew 18.34% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $38.0 million in 2022, then rose by 6.69% to $40.5 million in 2023, then rose by 8.48% to $43.9 million in 2024, then rose by 15.73% to $50.9 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Non-Current Debt are $50.9 million (Q3 2025), $41.1 million (Q2 2025), and $42.5 million (Q1 2025).